XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue (Tables)
6 Months Ended
Jun. 30, 2021
Revenue  
Schedule of reportable segment included under sales category

Three Months Ended June 30, 2021

Three Months Ended June 30, 2020

(in millions)

    

U.S.

    

Int’l

    

Total

    

U.S.

    

Int’l

    

Total

Established Pharmaceutical Products —

  

 

  

 

  

 

  

 

  

 

  

Key Emerging Markets

$

$

915

$

915

$

$

764

$

764

Other

 

 

265

 

265

 

 

249

249

Total

 

 

1,180

 

1,180

 

 

1,013

 

1,013

Nutritionals —

 

 

 

 

 

 

Pediatric Nutritionals

 

528

 

565

 

1,093

 

484

 

540

 

1,024

Adult Nutritionals

 

345

 

670

 

1,015

 

324

 

535

 

859

Total

 

873

 

1,235

 

2,108

 

808

 

1,075

 

1,883

Diagnostics —

 

 

 

 

 

 

Core Laboratory

 

283

 

1,023

 

1,306

 

289

 

698

 

987

Molecular

 

94

 

196

 

290

 

144

 

215

 

359

Point of Care

 

97

 

40

 

137

 

79

 

39

 

118

Rapid Diagnostics

 

681

 

833

 

1,514

 

345

 

185

 

530

Total

 

1,155

 

2,092

 

3,247

 

857

 

1,137

 

1,994

Medical Devices —

 

 

 

 

 

 

Rhythm Management

 

269

 

298

 

567

 

185

 

216

 

401

Electrophysiology

 

209

 

278

 

487

 

120

 

179

 

299

Heart Failure

 

168

 

59

 

227

 

115

 

43

 

158

Vascular

 

246

 

451

 

697

 

168

 

313

 

481

Structural Heart

 

191

 

231

 

422

 

91

 

132

 

223

Neuromodulation

 

166

 

44

 

210

 

85

 

21

 

106

Diabetes Care

289

767

1,056

202

553

755

Total

 

1,538

 

2,128

 

3,666

 

966

 

1,457

 

2,423

Other

 

15

 

7

 

22

 

7

 

8

 

15

Total

$

3,581

$

6,642

$

10,223

$

2,638

$

4,690

$

7,328

Note 3 — Revenue (Continued)

Six Months Ended June 30, 2021

Six Months Ended June 30, 2020

(in millions)

    

U.S.

    

Int’l

    

Total 

    

U.S.

    

Int’l

    

Total

Established Pharmaceutical Products —

 

  

 

  

 

  

 

  

 

  

  

Key Emerging Markets

$

$

1,736

$

1,736

$

$

1,577

$

1,577

Other

 

 

514

 

514

 

 

480

480

Total

 

 

2,250

 

2,250

 

 

2,057

 

2,057

Nutritionals —

 

 

 

 

 

 

Pediatric Nutritionals

 

1,036

 

1,123

 

2,159

 

1,002

 

1,111

 

2,113

Adult Nutritionals

 

673

 

1,312

 

1,985

 

618

 

1,056

 

1,674

Total

 

1,709

 

2,435

 

4,144

 

1,620

 

2,167

 

3,787

Diagnostics —

 

 

 

 

 

 

Core Laboratory

 

554

 

1,934

 

2,488

 

556

 

1,420

 

1,976

Molecular

 

269

 

468

 

737

 

209

 

289

 

498

Point of Care

 

189

 

77

 

266

 

182

 

74

 

256

Rapid Diagnostics

 

1,784

 

1,986

 

3,770

 

713

 

377

 

1,090

Total

 

2,796

 

4,465

 

7,261

 

1,660

 

2,160

 

3,820

Medical Devices —

 

 

 

 

 

 

Rhythm Management

 

510

 

576

 

1,086

 

413

 

462

 

875

Electrophysiology

 

388

 

530

 

918

 

284

 

403

 

687

Heart Failure

 

313

 

108

 

421

 

267

 

94

 

361

Vascular

 

465

 

867

 

1,332

 

398

 

708

 

1,106

Structural Heart

 

360

 

439

 

799

 

227

 

314

 

541

Neuromodulation

 

311

 

83

 

394

 

222

 

61

 

283

Diabetes Care

542

1,494

2,036

388

1,119

1,507

Total

 

2,889

 

4,097

 

6,986

 

2,199

 

3,161

 

5,360

Other

 

25

 

13

 

38

 

15

 

15

 

30

Total

$

7,419

$

13,260

$

20,679

$

5,494

$

9,560

$

15,054

Schedule of changes in contract liabilities

(in millions)

    

Contract Liabilities:

Balance at December 31, 2020

$

405

Unearned revenue from cash received during the period

280

Revenue recognized related to contract liability balance

(279)

Balance at June 30, 2021

$

406